Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Considering New Metrics To Evaluate Advisory Panel Member Conflicts

Executive Summary

In response to concerns about conflicts of interests involving advisory committee members, FDA has started to examine possible metrics to assess panelists' expertise and relationships with regulated companies
Advertisement

Related Content

FDA Gains No Impartiality Benefit From Conflict-Of-Interest Policy, Advocates Say
FDA Gains No Impartiality Benefit From Conflict-Of-Interest Policy, Advocates Say
Public Citizen's FDA? Lurie Is Consumer Group's Third In Key Agency Role
Public Citizen's FDA? Lurie Is Consumer Group's Third To Play Key Role At Agency
Advisory Committee Conflict Of Interest Waivers Get Support From Study
Draft Conflict Of Interest Policy Affects Status Of Many FDA Cmte. Members
FDA not heeding advisory committees
Gardasil Clears FDA, But Dosing May Pose Administrative Challenges
Advisory Panelist Conflicts Of Interest Have Weak Favorable Effect On Votes
Advisory Panelist Conflicts Of Interest Have Weak Favorable Effect On Votes
Advertisement
UsernamePublicRestriction

Register

PS047553

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel